Vera Therapeutics Inc’s filing revealed that its Chief Regulatory Officer Turner William D. unloaded Company’s shares for reported $0.5 million on Dec 15 ’25. In the deal valued at $50.08 per share,10,000 shares were sold. As a result of this transaction, Turner William D. now holds 22,500 shares worth roughly $1.21 million.
Then, ENRIGHT PATRICK G bought 5,882 shares, generating $249,985 in total proceeds. Upon buying the shares at $42.50, the Director now owns 5,882 shares.
Before that, WILLIAM TURNER bought 10,000 shares. Vera Therapeutics Inc shares valued at $498,000 were divested by the Officer at a price of $49.80 per share.
BofA Securities initiated its Vera Therapeutics Inc [VERA] rating to a Buy in a research note published on October 16, 2025; the price target was $48. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who decreased its forecast for the stock in early August from “an Outperform” to “a Peer perform”. Wolfe Research started covering the stock on February 04, 2025. It rated VERA as “an Outperform”.
Price Performance Review of VERA
On Monday, Vera Therapeutics Inc [NASDAQ:VERA] saw its stock jump 5.00% to $53.78. Over the last five days, the stock has gained 9.29%. Vera Therapeutics Inc shares have risen nearly 30.03% since the year began. Nevertheless, the stocks have risen 27.17% over the past one year. While a 52-week high of $51.72 was reached on 12/22/25, a 52-week low of $18.53 was recorded on 04/09/25.
Levels Of Support And Resistance For VERA Stock
The 24-hour chart illustrates a support level at 51.77, which if violated will result in even more drops to 49.76. On the upside, there is a resistance level at 55.18. A further resistance level may holdings at 56.58.
How much short interest is there in Vera Therapeutics Inc?
A steep rise in short interest was recorded in Vera Therapeutics Inc stocks on 2025-11-28, growing by 1.56 million shares to a total of 10.82 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 9.26 million shares. There was a rise of 14.41%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 28, 2025 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $58 price target.
